Sucampo (Nasdaq: SCMP) drug works in clinical trial

Orlando, FL 2/3/12 (StreetBeat) -- Bethesda-based Sucampo Pharmaceuticals Inc. (Nasdaq: SCMP) said its drug to treat bowel dysfunction in patients taking opioid-based painkillers worked in late stage clinical trials.

Sucampo, developing lubiprostone with Japanese partner Takeda Pharmaceuticals, said the drug met the primary endpoint in a Phase 3 clinical trial that involved 439 patients in the U.S. and Europe. It believes the drug now has the potential to be the first FDA-approved orally administered medicine to treat Opioid-induced Bowel Dysfunction, or OBD.

Sucampo said it expects to file with the Food and Drug Administration for a supplemental new drug application in the first half of 2012.

Sucampo stock gained $1.00 to $5.39 per share in Thursday trading.

StreetBeat Disclaimer

Distributed by Viestly